REG - Cizzle Biotechnology - China Royalty Agreement for Lung Cancer Detection

Cizzle Biotechnology HoldingsAnnouncement

03/02/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220203:nRSC5310Aa&default-theme=true

RNS Number : 5310A  Cizzle Biotechnology Holdings PLC  03 February 2022

This announcement contains inside information for the purposes of article 7 of
EU Regulation 596/2014 which forms part of domestic UK law pursuant to the
European Union (Withdrawal) Act 2018 ("UK MAR").  Upon the publication of
this announcement this inside information is now considered to be within the
public domain.

 

3 February 2022

Cizzle Biotechnology Holdings Plc

 

("Cizzle Biotechnology" or the "Company")

 

Royalty Strategic Alliance for Early Lung Cancer Detection in China

 

Cizzle Biotechnology, the UK based diagnostics developer, is pleased to
announce that following the signing of a Memorandum of Understanding ("MOU")
with the International Co-Innovation Centre for Advanced Medical Technology
("iCCAMT") and Shenzhen Intelliphecy Life Technologies Co., Ltd.
("Intelliphecy"), announced on 25 November 2021, a full commercial agreement
has now been executed to develop and market the Company's proprietary early
lung cancer diagnostic tests in China (the "Agreement").

 

Highlights

 

·    Commercial agreement reached with iCCAMT and Intelliphecy

·    iCCAMT backers include German Medical Valley, Robert Bosch GmbH and
Sinopharm Group

·    iCCAMT and Intelliphecy to fund all activities in China, including
development, clinical trials, manufacture and distribution

·    10% royalty for the Company over all sales of products and services
using CIZ1B in China

·    Initial pilot of 300 patients planned

Background

Around 816,000 new lung cancer cases were diagnosed in China in 2020,
accounting for almost 18 percent of all the 4.6 million new cancer cases in
China. In that year, approximately three million deaths in China were caused
by cancer*. It is also known that there are serious challenges in being able
to detect cancer early and a great need for screening and diagnosing cancers
among the Chinese population when targeted interventions can improve timely
access to cancer care and save lives**.

The Agreement

The Agreement will generate future revenues for Cizzle Biotechnology via a 10%
royalty on the sales of all products and services using its proprietary CIZ1B
technology and from payment for monoclonal antibodies and reagents.

The China partners will be solely responsible for funding all activities in
China including development, clinical trials, manufacturing, and distribution.
It is intended that initial development will commence within 60 days of Cizzle
Biotechnology supplying its immunoreagents to the China partners, which is
anticipated to be in Q2 2022.

An initial pilot covering 300 patients is planned at China's premier cancer
hospitals, which will allow for a true representative patient cohort to be
included and, if successful, is expected to accelerate adoption and product
rollout in China.

The China partners

iCCAMT, founded with German Medical Valley, Robert Bosch GmbH and Sinopharm
Group, aims to accelerate global med-tech innovation in the Chinese market, by
bringing together world leading expertise. The strategic alliance is intended
to accelerate product development and clinical trials to achieve early
adoption within major cancer centers throughout China.

Intelliphecy is aiming to innovate technologies in the hope to win the war
against cancer, aspiring to out-smart cancer cells with an intelligent
prophecy. At the core of Intelliphecy's technology portfolio lies artificial
intelligence driven big data analytics, which is devoted to predictive
modeling of cancer, a methodology which has proved timely given the global
pandemic's digital health and data adoption trends.

Commenting, Allan Syms, Executive Chairman of Cizzle Biotechnology, said:

"As reported in November 2021, when we signed our MOU with iCCAMT and
Intelliphecy, lung cancer in China is a huge social and economic challenge,
especially because of the difficulties in being able to detect it early enough
to make clinical intervention effective. We are now pleased to report that as
planned we have completed detailed commercial negotiations and have entered
into a full binding agreement that will enable us to bring our early cancer
testing technology to this important market. Our Chinese partners will be
financing all activities in China in exchange for providing us with important
and repeatable royalty revenues and covering the costs for all key reagents
and our proprietary monoclonal antibodies. We are excited to be working with
our new partners in China and look forward to beginning our initial pilot
trials with China's leading scientists and centers of excellence."

Commenting, Dr Hui Wu, CEO and Founder of iCCAMT said:

"This agreement represents a significant opportunity to bring early and
cost-effective cancer detection to the people of China. It is estimated that
about 95.8 million people in China have a high risk of lung cancer and if
screening was performed every three years, then more than 30 million tests per
year would be required. At a target price of about £100 per test, the total
available market for tests based on the CIZ1B biomarker would be £3 billion.
(Frost & Sullivan estimates the market size in China is US$5.7 billion).
We have already secured strong interest from our nationwide network of
national clinical centers and key opinion leaders because of the promising
results using the CIZ1B biomarker for lung cancer early detection in the UK
and one our first tasks is to commence pilot studies at the Cancer Hospital,
Chinese Academy of Medical Sciences, National Cancer Centre, and Beijing
Cancer Hospital, affiliated with Peking University."

Commenting, Dr Xiaoyun Huang, CEO and Founder of Intelliphecy said:

"Lung cancer is the one with the highest incidence in China. The fact that
many lung cancer patients are diagnosed with advanced disease hampers
therapeutic efficiency and patient survival. There is an urgent need for early
lung cancer detection in China. We are extremely happy to have finalized the
details of a formal agreement on a Royalty Strategic Alliance for Early Lung
Cancer Detection in China with Cizzle and iCCAMT. This marks the first
milestone of our strategic alliance since the signing of MOU. We are looking
forward to initiating the development of CIZ1B based early lung cancer
detection products and services as soon as possible."

 

Enquiries:

 

 Cizzle Biotechnology Holdings plc  Via IFC Advisory
 Allan Syms (Executive Chairman)

 

 Allenby Capital Limited  +44(0) 20 33285656
 John Depasquale
 Alex Brearley

 

 Novum Securities Limited  +44(0) 20 7399 9400
 Colin Rowbury

 Jon Bellis

 

 IFC Advisory Limited  +44(0) 20 3934 6630
 Tim Metcalfe          cizzle@investor-focus.co.uk
 Florence Chandler

 

Notes to Editors:

About Cizzle Biotechnology

Cizzle Biotechnology is developing a blood test for the early detection of
lung cancer.  Cizzle Biotechnology is a spin- out from the University of
York, founded in 2006 around the work of Professor Coverley and colleagues.
Its proof-of-concept prototype test is based on the ability to detect a stable
plasma biomarker, a variant of CIZ1 known as CIZ1B.  CIZ1 is a naturally
occurring cell nuclear protein involved in DNA replication, and the targeted
CIZ1B variant is highly correlated with early stage lung cancer.

For more information, please see https://cizzlebiotechnology.com
(https://cizzlebiotechnology.com)

You can also follow the Company through its twitter account @CizzlePlc and on
LinkedIn.

About International Co-Innovation Centre for Advanced Medical Technology
("iCCAMT")

iCCAMT, founded with German Medical Valley, Robert Bosch GmbH, Sinopharm
Group, aims to accelerate global healthcare innovation in China. iCCAMT is
dedicated to support innovative healthcare SMEs (small and medium sized
companies) to grow in China and promote technology transfer. With global
health technology network and supports from industry giants, iCCAMT has
developed comprehensive platforms to strengthen cross-border health technology
collaborations, and help global health technology companies enter the China
market.

For more information, please see http://www.iccamt.com (http://www.iccamt.com)
 

About Shenzhen Intelliphecy Life Technologies Co., Ltd. ("Intelliphecy")

Intelliphecy is aiming to innovate technologies in the hope to win the war
against cancer, aspiring to out-smart cancer cells with an intelligent
prophecy. At the core of Intelliphecy's technology portfolio lies artificial
intelligence driven big data analytics, which is devoted to predictive
modeling of cancer hallmarks using quantitative information. Its research and
development is grounded in both identification of cancer at early stage and
prediction of optimal treatment strategies for individual cancer patients.
Intelliphecy has established research collaborations with major cancer centres
throughout China.

For more information, please see http://www.intelliphecy.com
(http://www.intelliphecy.com)

About the Cancer Hospital, Chinese Academy of Medical Sciences, National
Cancer Centre

The Cancer Institute and Hospital, Chinese Academy of Medical Sciences (CAMS),
is located in the southeastern part of Beijing. It was built in 1958 and is a
national center of advanced cancer research and treatment, which is also rated
in first place for cancer prevention and treatment in Asia in terms of scale.
It is one of the WHO collaborative centers for cancer research in China and
one of the bases for drug clinical trials for the Food and Drug Administration
of State (SFDA). It offers advanced cancer treatment, engages in cancer
research, comprehensive education and research-based prevention of both common
and rare cancers. It is considered a "state-level hospital" with comprehensive
oncology departments, strong technical force and advanced medical equipment.
The major treatments include surgery, chemotherapy, radiotherapy, biological
therapy, intervenient therapy, and laser therapy.

About Beijing Cancer Hospital affiliated with Peking University

Peking University Cancer Hospital & Institute is one of the top academic
cancer centers in China. It is devoted to offering the best of evidence-based
and patient-centered medical care, conducting high-level basic and
translational researches, and providing high-quality basic medical teaching
and specialisation training programs. Peking University Cancer Hospital &
Institute is one of the most versatile cancer centers in China, using surgery,
radiation therapy, chemotherapy and interventional therapy to treat a wide
range of tumors, especially gastrointestinal cancers, breast cancer, melanoma,
lymphoma, liver cancer and lung cancer. It advocates multidisciplinary
cooperation, integrating all available expertise and resources to offer
patients the best tailored comprehensive therapies possible. Peking University
Cancer Hospital & Institute has a strong capacity in basic and clinical
studies on cancer. There are more than 140 talented researchers working in 10
laboratories equipped with the most advanced apparatus and up-to-date research
technologies in cell biology, proteomics and genomics. Prominent progress has
been achieved in research on carcinogenesis, cancer prevention, biology,
epidemiology and biotherapy relating to the most common cancers in China,
especially gastric cancer and breast cancer.

References

*https://www.statista.com/statistics/1042899/china-new-cancer-case-number/

**
https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(21)00157-2/fulltext
(https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(21)00157-2/fulltext)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGREAPAAESAAEFA